BRAF and acral lentiginous melanoma: In a subgroup analysis of patients with acral melanoma by BRAF mutation status (BRAF wild type, n = 34; BRAF mutant, n = 4), ORR was 20.6% (95% CI, 8.7–37.9; 0 CR/7 PR) in patients with BRAF wild-type disease and 0% in the 4 patients with BRAF-mutant disease (Table 3).